Status:
RECRUITING
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
Lead Sponsor:
HudsonAlpha Institute for Biotechnology
Conditions:
Cognitive Impairment
Alzheimer Blood Biomarkers
Eligibility:
All Genders
65-75 years
Phase:
NA
Brief Summary
Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments i...
Eligibility Criteria
Inclusion
- Adults 65-75 years of age at enrollment with at least one self-reported 1st-degree relative who had or has any kind of dementia
- Montreal Cognitive Assessment (MoCA) score \> 24 at initial enrollment
- Able and willing to comprehend and sign the informed consent document
- Able and willing to perform required physical performance tests
- Able and willing to provide the study's minimum samples
- Able and willing to conduct the study's minimum procedures
- Able and willing to complete surveys, cognitive assessments, and questionnaires in English only
- Has or has ready access to a PC, tablet, or smartphone with an internet connection required for procedures that they consent to
Exclusion
- A diagnosis of cognitive impairment of any kind, including Alzheimer's disease, mild cognitive impairment, or any other diagnosis of dementia
- If a subject is found to have cognitive impairment at initial enrollment (Montreal Cognitive Assessment (MoCA) score\<25), they will be excluded from the study
- Self-reported pregnancy
- Children under 19 years of age
- Individuals not fluent in written and spoken English
- Self-reported chronic or end-stage disease that would interfere with their participation in the study
- Hospitalization for any reason in the past 3 months
- Severe hearing and visual impairment that would interfere with the ability to complete study measures
- Any other vulnerable subject at the time of enrollment as specified above
Key Trial Info
Start Date :
May 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07146412
Start Date
May 2 2025
End Date
April 30 2026
Last Update
August 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Smith Family Clinic for Genomic Medicine
Huntsville, Alabama, United States, 35806